Updated

A study found that tirzepatide, sold as Mounjaro and Zepbound, activated calorie-burning brown fat in obese mice, revealing a potential metabolic effect beyond its known appetite-suppressing action. If confirmed in humans, the discovery could help explain the drug's powerful weight-loss and metabolic benefits and inspire further treatments for obesity and diabetes built around activating brown fat.